ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TMDX TransMedics Group Inc

149.23
-2.58 (-1.70%)
After Hours
Last Updated: 21:16:19
Delayed by 15 minutes
Share Name Share Symbol Market Type
TransMedics Group Inc NASDAQ:TMDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.58 -1.70% 149.23 146.10 151.15 153.52 146.3901 148.51 571,386 21:16:19

TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024

17/07/2024 9:05pm

PR Newswire (US)


TransMedics (NASDAQ:TMDX)
Intraday Stock Chart


Wednesday 17 July 2024

Click Here for more TransMedics Charts.

ANDOVER, Mass., July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

(PRNewsfoto/TransMedics, Inc.)

Investors interested in listening to the conference call may do so by dialing (866) 807-9684 for domestic callers or (412) 317-5415 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.   

About TransMedics Group, Inc. 
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-second-quarter-2024-financial-results-on-july-31-2024-302199738.html

SOURCE TransMedics Group, Inc.

Copyright 2024 PR Newswire

1 Year TransMedics Chart

1 Year TransMedics Chart

1 Month TransMedics Chart

1 Month TransMedics Chart

Your Recent History

Delayed Upgrade Clock